JPRN-UMIN000029310Recruiting未知
Impact of anti-PCSK9 antibody Alirocumab on lipid-lowering on patient motivation to treatment for hypercholesterolemia. - Impact of Alirocumab on patient motivation to treatment.
Minamiosaka Hospital Department of Internal Medicine0 sites10 target enrollmentStarted: October 1, 2017Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Pregnant 2)Drug allergy to Alirocumab 3)Unsuitable patients for this study by physicians decision
Investigators
Similar Trials
Terminated
Phase 2
Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic SyndromeNephrotic SyndromeNCT03004001Gloria Vega3
Completed
Phase 1
Alirocumab in Patients with SepsisSepsisNCT05469347Jonathan Sevransky50
Completed
Not Applicable
egacy Effects of PCSK9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaqueacute coronary syndromeJPRN-UMIN000041925Gifu Heart Center7
Completed
Phase 2
Effect of Alirocumab on Lipoprotein(a) (Lp(a)) Metabolism in Subjects with Moderate to High Risk of Heart DiseaseCardiovascular Disease (CVD)Cardiovascular - Coronary heart diseaseACTRN12617000401358inear Clinical Research Ltd.21
Active, not recruiting
Phase 2
Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial AtherosclerosisIntracranial AtherosclerosisAcute Ischemic StrokeICAS - Intracranial AtherosclerosisNCT05001984Chang Gung Memorial Hospital60